诱杀受体3——肿瘤基因治疗的新靶点  

Decoy Receptor 3:A Novel Target for Gene Therapy of Cancer

作　　者：张胜行[1] 兰小鹏[1] 

机构地区：[1]福建医科大学临床教学基地,福州总医院全军检验医学研究所,福建福州350025

出　　处：《生物技术通讯》2008年第2期271-273,共3页Letters in Biotechnology

基　　金：福建省科技厅国际合作重点项目(2004I012)

摘　　要：诱杀受体3(DcR3)又称肿瘤坏死因子受体(TNFR)6B,是最近发现的TNFR超家族成员之一。DcR3是一种凋亡抑制蛋白,能够抑制肿瘤细胞凋亡,促进肿瘤细胞免疫逃避。研究显示,DcR3在人类正常分化组织中很少表达,却特异性表达在常见的肿瘤,它的表达上调可预示肿瘤恶性程度和预后。作为肿瘤分子标志物,体液及组织中高水平的DcR3表达能够辅助肿瘤诊断和治疗监测。应用分子生物技术可以抑制肿瘤细胞中DcR3的表达,从而诱导肿瘤细胞的凋亡。Decoy receptor 3（DcR3） or tumor necrosis factor receptor（TNFR） 6B is a newly discoverable member of TNFR superfamily. DcR3 is a kind of inhibition of apoptosis protein, which can inhibit apoptosis and make tumor cells immunity escape easily. Recent researches showed that DcR3 was expressed selectively in most human common tumors but not in normal tissue, and its up-regulation predicted the toumor＇s malignancy degree and poor prognosis of tumor patients. As a molecular marker of tumor, high-level of DcR3 in body fluid can help detecting tumors and therapy monitoring. The tumor cells could be induced to apoptosis easily after inhibiting the expression of DcR3 gene by the novel biology technology.

关 键 词：诱杀受体3 FAS配体 LIGHT TL1A 基因治疗 

分 类 号：R730.231[医药卫生—肿瘤]